OncoMatch/Clinical Trials/NCT02727803
Personalized NK Cell Therapy in CBT
Is NCT02727803 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for accelerated phase chronic myelogenous leukemia, bcr-abl1 positive.
Treatment: Allogeneic Natural Killer Cell Line NK-92 · Anti-Thymocyte Globulin · Busulfan · Clofarabine · Cyclophosphamide · Fludarabine Phosphate · Melphalan · Rituximab — This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Myeloid Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Hodgkin Lymphoma
Biomarker criteria
Allowed: KMT2A (MLL) rearrangement
myeloid/lymphoid or mixed-lineage leukemia [MLL] gene re-arrangement
Allowed: FLT3 mutation
flt3 mutation positive
Allowed: BCR fusion
translocations 9;22
Allowed: ABL1 fusion
translocations 9;22
Allowed: KMT2A (MLL) translocation t(4;11)
translocations 4;11
Allowed: MYC rearrangement
double hit non-Hodgkin's lymphoma
Allowed: BCL2 rearrangement
double hit non-Hodgkin's lymphoma
Allowed: BCL6 rearrangement
double hit non-Hodgkin's lymphoma
Disease stage
Required: Stage II, III
ISS Stage II Plasma Cell Myeloma; ISS Stage III Plasma Cell Myeloma
Prior therapy
Must have received: standard therapy
progressive disease following a minimum of two lines of standard therapy
Lab requirements
Kidney function
Serum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or glomerular filtration rate [GFR]) > 40mL/min/1.73 m^2
Liver function
SGPT/bilirubin < to 2.0 x normal (myeloablative regimen 1), reduced intensity regimen 3; SGPT/bilirubin < to 4.0 x normal (nonmyeloablative regimen 2)
Cardiac function
Left ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3); Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)
Left ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3); Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2); Pulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration (myeloablative regimen 1, reduced intensity regimen 3); Serum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or glomerular filtration rate [GFR]) > 40mL/min/1.73 m^2; SGPT/bilirubin < to 2.0 x normal (myeloablative regimen 1), reduced intensity regimen 3; SGPT/bilirubin < to 4.0 x normal (nonmyeloablative regimen 2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify